David Miklos

Publications

• H-Y antigen-binding B cells develop in male recipients of female hematopoietic cells and associate with chronic graft vs. host disease. Sahaf B, Yang Y, Arai S, Herzenberg LA, Herzenberg LA, Miklos DB. Proc Natl Acad Sci U S A. 2013; 110 (8): 3005-10
• Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia. Logan AC, Zhang B, Narasimhan B, Carlton V, Zheng J, Moorhead M, Krampf MR, Jones CD, Waqar AN, Faham M, Zehnder JL, Miklos DB. Leukemia. 2013
• Massive evolution of the immunoglobulin heavy chain locus in children with B precursor acute lymphoblastic leukemia. Gawad C, Pepin F, Carlton VE, Klinger M, Logan AC, Miklos DB, Faham M, Dahl G, Lacayo N. Blood. 2012; 120 (22): 4407-17
• Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. Arai S, Sahaf B, Narasimhan B, Chen GL, Jones CD, Lowsky R, Shizuru JA, Johnston LJ, Laport GG, Weng WK, Benjamin JE, Schaenman J, Brown J, Ramirez J, Zehnder JL, Negrin RS, Miklos DB. Blood. 2012; 119 (25): 6145-54
• High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment. Logan AC, Gao H, Wang C, Sahaf B, Jones CD, Marshall EL, Buño I, Armstrong R, Fire AZ, Weinberg KI, Mindrinos M, Zehnder JL, Boyd SD, Xiao W, Davis RW, Miklos DB. Proc Natl Acad Sci U S A. 2011; 108 (52): 21194-9
• Measurement and clinical monitoring of human lymphocyte clonality by massively parallel VDJ pyrosequencing. Boyd SD, Marshall EL, Merker JD, Maniar JM, Zhang LN, Sahaf B, Jones CD, Simen BB, Hanczaruk B, Nguyen KD, Nadeau KC, Egholm M, Miklos DB, Zehnder JL, Fire AZ. Sci Transl Med. 2009; 1 (12): 12ra23
• Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Miklos DB, Kim HT, Miller KH, Guo L, Zorn E, Lee SJ, Hochberg EP, Wu CJ, Alyea EP, Cutler C, Ho V, Soiffer RJ, Antin JH, Ritz J. Blood. 2005; 105 (7): 2973-8
• Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation. Johnston L, Florek M, Armstrong R, McCune JS, Arai S, Brown J, Laport G, Lowsky R, Miklos D, Shizuru J, Sheehan K, Lavori P, Negrin R. Bone Marrow Transplant. 2012; 47 (4): 581-8
• A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies. Chen GL, Arai S, Flowers ME, Otani JM, Qiu J, Cheng EC, McMillan A, Johnston LJ, Shizuru JA, Miklos DB. Blood. 2011; 118 (15): 4070-8
• Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Laport GG, Sheehan K, Baker J, Armstrong R, Wong RM, Lowsky R, Johnston LJ, Shizuru JA, Miklos D, Arai S, Benjamin JE, Weng WK, Negrin RS. Biol Blood Marrow Transplant. 2011; 17 (11): 1679-87
• B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies. Winer DA, Winer S, Shen L, Wadia PP, Yantha J, Paltser G, Tsui H, Wu P, Davidson MG, Alonso MN, Leong HX, Glassford A, Caimol M, Kenkel JA, Tedder TF, McLaughlin T, Miklos DB, Dosch HM, Engleman EG. Nat Med. 2011; 17 (5): 610-7
• Clonally identical Hodgkin's disease develops after allogeneic hematopoietic cell transplant for CLL. Tseng D, Jones CD, Anderson M, Warnke R, Zehnder JL, Miklos DB. Bone Marrow Transplant. 2011; 46 (12): 1576-8
• Combined CD4 T-cell and antibody response to human minor histocompatibility antigen DBY after allogeneic stem-cell transplantation. Porcheray F, Miklos DB, Floyd BH, Sarantopoulos S, Bellucci R, Soiffer RJ, Antin JH, Alyea EP, Ritz J, Zorn E. Transplantation. 2011; 92 (3): 359-65
• Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY. Naik S, Wong R, Arai S, Brown J, Laport G, Lowsky R, Miklos D, Shizuru J, Blume K, Negrin R, Johnston L. Bone Marrow Transplant. 2011; 46 (2): 192-9
• Protein microarrays discover angiotensinogen and PRKRIP1 as novel targets for autoantibodies in chronic renal disease. Butte AJ, Sigdel TK, Wadia PP, Miklos DB, Sarwal MM. Mol Cell Proteomics. 2011; 10 (3): M110.000497
• Recombinant antigen microarrays for serum/plasma antibody detection. Wadia PP, Sahaf B, Miklos DB. Methods Mol Biol. 2011: 723 81-104
• Allogeneic T cells impair engraftment and hematopoiesis after stem cell transplantation. Müller AM, Linderman JA, Florek M, Miklos D, Shizuru JA. Proc Natl Acad Sci U S A. 2010; 107 (33): 14721-6
• Antibodies specifically target AML antigen NuSAP1 after allogeneic bone marrow transplantation. Wadia PP, Coram M, Armstrong RJ, Mindrinos M, Butte AJ, Miklos DB. Blood. 2010; 115 (10): 2077-87
• Complete donor T-cell engraftment 30 days after allogeneic transplantation predicts molecular remission in high-risk chronic lymphocytic leukaemia. Jones CD, Arai S, Lowsky R, Tyan DB, Zehnder JL, Miklos DB. Br J Haematol. 2010; 150 (5): 637-9
• Individual variation in the germline Ig gene repertoire inferred from variable region gene rearrangements. Boyd SD, Gaëta BA, Jackson KJ, Fire AZ, Marshall EL, Merker JD, Maniar JM, Zhang LN, Sahaf B, Jones CD, Simen BB, Hanczaruk B, Nguyen KD, Nadeau KC, Egholm M, Miklos DB, Zehnder JL, Collins AM. J Immunol. 2010; 184 (12): 6986-92
• Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory hodgkin lymphoma. Arai S, Letsinger R, Wong RM, Johnston LJ, Laport GG, Lowsky R, Miklos DB, Shizuru JA, Weng WK, Lavori PW, Blume KG, Negrin RS, Horning SJ. Biol Blood Marrow Transplant. 2010; 16 (8): 1145-54
• Rituximab in hematopoietic cell transplantation. Arai S, Miklos DB. Expert Opin Biol Ther. 2010; 10 (6): 971-82
• Identifying compartment-specific non-HLA targets after renal transplantation by integrating transcriptome and "antibodyome" measures. Li L, Wadia P, Chen R, Kambham N, Naesens M, Sigdel TK, Miklos DB, Sarwal MM, Butte AJ. Proc Natl Acad Sci U S A. 2009; 106 (11): 4148-53
• TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Kohrt HE, Turnbull BB, Heydari K, Shizuru JA, Laport GG, Miklos DB, Johnston LJ, Arai S, Weng WK, Hoppe RT, Lavori PW, Blume KG, Negrin RS, Strober S, Lowsky R. Blood. 2009; 114 (5): 1099-109
• H-Y antibody development associates with acute rejection in female patients with male kidney transplants. Tan JC, Wadia PP, Coram M, Grumet FC, Kambham N, Miller K, Pereira S, Vayntrub T, Miklos DB. Transplantation. 2008; 86 (1): 75-81
• Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. Miklos DB, Kim HT, Zorn E, Hochberg EP, Guo L, Mattes-Ritz A, Viatte S, Soiffer RJ, Antin JH, Ritz J. Blood. 2004; 103 (1): 353-9